## Krebs Biochemicals & Industries Limited

CIN: L24110AP1991PLC103912



Date-13-04-021

To

**ARPIT GANGWANI** 

Email: arpit.gangwani@bseindia.com

Bombay stock exchange

Reference: Your email dated 12th April, 2021 with reference number NSE/CM/Surveillance/ 10553

Subject:Reply to the Clarification on Price sensitive information and intimation on Compliance under Regulation 30 of SEBI (Listing obligations and Disclosure) (LODR)' 2015

Dear Sir,

With respect to the Quoted subject, we hereby clarify you that the Company has duly informed the exchange on all ma6rial disclosures that is obligated to give under SEBI (LODR), 2015 and especially with respect to Regulation 30.

The latest information given to stock exchanges are with respect to

Date	Particulars	
23-01-2021	Board Meeting Intimation for Notice Of Board Meeting To	
	Be Held On 30Th January, 2021	
30-01-2021	Update On Results And Outcome Of Board Meeting Held	
	On 30 <sup>th</sup> January, 2021	
27-03-2021	Closure of Trading Window	
04-04-2021	Announcement under Regulation 30 (LODR) and outcome	
	of Board meeting-Regards conversion of warrants in equity	
	shares and allotment to M/s Ipca Laboratories Limited	
	(Promoter)	

Other than the above Announcement/information, the Company has informed the exchanges regards outcome of Board meeting, Quarterly Financials, and such other compliances under various Regulations of SEBI (LODR), 2015.

The company has not suppressed any information which ought to be disclosed by law and neither has the intention to hide any materialistic information which may be treated as Price sensitive information'.



Regd. Office: Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031 Corporate Office: 8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034Tel: 040-66808040 E-mail mar keting@krebsbiochem.com Website www.krebsbiochem.com

## Krebs Biochemicals & Industries Limited

CIN: L24110AP1991PLC103912



The significant Price changes/movements that have occurred and observed by you' have no bearing on the non-disclosure of any major information as enunciated in your email' the same might have occurred due to the general market movement which the company does not have any control on.

For Krebs Biochemicals and Industries Limited



Company secretary